Directorio de ensayos clínicos

A phase 1/2a, open-label dose escalation and cohort expansion study of orally administered ca-4948 (irak4i) as a monotherapy in patients with acute myelogenous leukemia or myelodysplastic syndrome and in combination with azacitidine or venetoclax.

FASE/S DEL ENSAYOFase I, Fase IIPATOLOGÍA Leucemia mieloide aguda CENTRO INVESTIGADORHospital Universitario de La PrincesaINVESTIGADOR PRINCIPAL Valle Gómez

Buscar:

Hospital General Universitario Gregorio Marañón Hospital Universitario de La Princesa Javier Loscertales Leucemia mieloide aguda Mielofibrosis Primaria Patricia Font Síndromes mielodisplásicos Valle Gómez

Accesos rápidos



Sociedad Aragonesa de Hematología y Hemoterapia

Nombre

Dirección de correo electrónico

Mensaje

8 + 2 =

Contacto

secretaria@sarhh.es

Información legal

Aviso legal

Política de cookies

Material utilizado

Esta web utiliza cookies propias y de terceros para mejorar la experiencia de navegación. Al continuar con la navegación entendemos que se acepta nuestra politica de cookies.Acepto Leer más

Privacidad y política de cookies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Siempre activado

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

GUARDAR Y ACEPTAR

Directorio de ensayos clínicos

A phase 1/2a, open-label dose escalation and cohort expansion study of orally administered ca-4948 (irak4i) as a monotherapy in patients with acute myelogenous leukemia or myelodysplastic syndrome and in combination with azacitidine or venetoclax.

Accesos rápidos

Jornadas

Grupos de trabajo

Estatutos

Directorio de socios/as

Sociedad Aragonesa de Hematología y Hemoterapia

Contacto

Información legal